Scott M. Hynes

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

David S. Hong, Jeffrey R. Infante, Filip Jankú et al. · Journal of Clinical Oncology · 2016 · 160 citations

Medicine, Oncology, Pharmacology +17

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

Berta Laquente, José A. López-Martín, Donald Richards et al. · BMC Cancer · 2017 · 74 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Jin Hyoung Kang, David C. Smith, Richard K. Rosenberg et al. · Investigational New Drugs · 2016 · 68 citations

Medicine, Oncology, Pharmacology +12

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Emiliano Calvo, Victor J. Chen, Mark S. Marshall et al. · Investigational New Drugs · 2014 · 57 citations

Medicine, Oncology, Pharmacology +7

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

Glen J. Weiss, Ross C. Donehower, Tara Iyengar et al. · Investigational New Drugs · 2012 · 56 citations

Medicine, Oncology, Pharmacology +13